Neuraxpharm Group, a provider of treatments for central nervous system (CNS) disorders, is set to introduce its first probiotic in the European market.
Neuraxpharm has entered into an exclusive licensing agreement with the probiotics company Bened Biomedical, under which Neuraxpharm secured exclusive rights to market its first probiotic lactobacillus plantarum PS128 in the European market.
Neuraxpharm CEO Dr. Jörg-Thomas Dierks said: “We are delighted to launch our first probiotic into the European market. Our mission is to raise the standards of mental health care, and we continue to be committed to offering diversified and affordable products.”
The new consumer healthcare product, which will be manufactured in Europe, will be first introduced in the Italian market and later in other European countries.
A recently published clinical trial and other peer-reviewed scientific papers showed the efficacy of lactobacillus plantarum PS128, said Neuraxpharm.
The company is also planning to begin a series of clinical studies on various mental health disorders to further develop this probiotic.
Neuraxpharm said that its first launch of a probiotic product expand its portfolio of marketed consumer healthcare products and is in line with its aim of covering CNS therapeutics from prevention over standard therapeutics to value-added medicines.
Bened Biomedical CEO Frankie Cheng said: “I am enthusiastic to bring PS128™ to the European market. We look forward to implementing this agreement with Neuraxpharm as it offers a unique approach to the support of people battling CNS disorders, which we believe will be welcomed by doctors and patients alike.”
Bened Biomedical, which is a 2015 spin-out from Taiwan-based National Yang-Ming University, is involved in the development of functional probiotic strains that can modify human microbiome.
Bened Biomedical offers microbiome-based therapy for neuropsychological, allergic, immunological, metabolic, and aging-related disorders.
Neuraxpharm provides a range of therapeutic products for depression, psychosis / schizophrenia, epilepsy, Parkinson’s, and Alzheimer’s disease.
The company is a major European specialty pharmaceutical company that carries out operations in Germany, Spain, Italy, France, the UK Poland, Czech Republic, Slovakia and Hungary.